The University of Missouri School of Medicine Department of Emergency Medicine is joining a nationwide study to evaluate repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19.
Repurposed medications are those that are FDA approved for other indications.
The double-blind study looks to enroll 15,000 patients nationwide.
The three medications being studied are Fluticasone, an inhaled steroid typically used for asthma, 
Fluvoxamine, typically prescribed for depression, 
and the anti-parasitic drug Ivermectin.
Study participants must be over 30 years old and have had a positive COVID-19 test in the last 10 days and have suffered from at least two symptoms.
To enroll, visit https://activ6study.org or call 833-385-1880.